2024 Annual Meeting Abstract Submissions

Scientific material must be original. It cannot be previously published in abstract or manuscript form. It also cannot be currently accepted for publication or presentation at another meeting prior to the USCAP 2024 Annual Meeting, March 23-28, 2024. Authors may submit as many abstracts as they wish; there is no limit to the number of co-authored abstracts. However, no more than three abstracts will be accepted from any first author. If more than three first-author abstracts are submitted, the lowest scoring abstract(s) will be immediately rejected. Abstracts are reviewed in a blinded fashion. Please do not include any identifying information such as institutional names or specific names for institutional assays in the body of the abstract. View the complete rules and submission guidelines below.

All abstracts submitted to the USCAP 2024 Annual Meeting must meet the eligibility requirements below:

• Scientific material must be original.
• Abstracts are not eligible for consideration if the abstract has been presented at a major national or international meeting prior to the USCAP 2024 Annual Meeting, March 23-28, 2024.
• Abstracts cannot be previously published, online or in print, prior to the USCAP 2024 Annual Meeting, March 23-28, 2024.
• If the accepted abstract is also submitted as a manuscript for publication prior to the USCAP 2024 Annual Meeting, the authors are responsible for coordinating with the journal to determine a publication date that abides by USCAP’s embargo policy. Abstracts related to manuscripts that are published online or in print before the USCAP 2024 Annual Meeting, March 23-28, 2024, must be withdrawn. Please notify the Academy via e-mail at [email protected].
  • If authors choose to submit a manuscript to Modern Pathology or Laboratory Investigation prior to the abstract presentation at the USCAP 2024 Annual Meeting, March 23-28, 2024, they will need to indicate this on the submission form and in the cover letter for the journal submission. USCAP has an agreement with these journals to withhold approved manuscripts from publication until the embargo is lifted.
• All abstracts must follow USCAP’s embargo policy. Any abstract found to be presented or published prior to the USCAP 2024 Annual Meeting, March 23-28, 2024 will be removed from the program.
• USCAP will examine all abstracts with anti-plagiarism software to verify the originality of the work. Flagged abstracts will be manually reviewed and those that represent only an incremental advance or lack sufficient novelty compared with published abstracts will be rejected.

Author Eligibility

• Individuals may submit as many abstracts as they wish; however, no more than three abstracts will be accepted from any first author. If more than three first-author abstracts are submitted, the lowest scoring abstracts will be immediately rejected.
• Individuals may serve as a coauthor on an unlimited number of abstracts.

USCAP has zero tolerance for any commercial bias in abstracts and the content must be presented objectively. Reviewers are instructed to reject any abstract which does not meet these criteria.

• Each author must complete an Author Disclosure Form for each abstract submitted; this can be done as soon as the author has been added to an abstract. The abstract does NOT need to be final in order to submit a disclosure.
• Upon entry of an author, an automatic email is sent from the system requesting the author login and complete a disclosure. The first author is responsible for ensuring all authors complete their disclosures.
• No abstract will be accepted for a platform presentation without completed disclosure forms from ALL authors. Authors must note any relevant relationships with companies in the event that their products and/or services are discussed in the abstract. All relationships, or absence of relationships, must be disclosed to the audience.

As an accredited provider of continuing medical education (CME) by the Accreditation Council for Continuing Medical Education (ACCME), USCAP complies with the Standards for Integrity and Independence in Accredited Continuing Education. To ensure the CME activities USCAP offers are independent and free of commercial bias, the USCAP CME Subcommittee reviews all disclosures from all authors on accepted abstracts that were submitted for platform presentation consideration. If there is not a reasonable way to resolve the conflicts of interest on an abstract, the abstract presentation preference may be changed to poster only. This decision is made by the CME Subcommittee following a thorough review of the disclosures and the abstract content.

This policy is not intended to prevent authors with commercial relationships from making a presentation. Disclosure of relevant relationships is required to help maintain objectivity and allow audience members to form their own judgments regarding the merit of material presented with the benefit of full disclosure of facts. Relationships that are not relevant to the content of the abstract need not be disclosed.

Policy on Unlabeled/Off-Label Use
USCAP has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). USCAP requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. All references to unlabeled/off-label use of products in the abstract must be disclosed on the poster when presented.

Abstracts from Industry
If accepted, abstracts submitted by Industry-affiliated authors or institutions will be defaulted to a poster presentation. They must only display research findings. No advertising or product identification by brand name is allowed. Commercial, product, and company logos cannot be placed on posters or poster boards. Posters that contain any type of commercial promotion, as described above, will be removed from the poster hall immediately without notice to the presenter.

All posters presented by industry must include a disclosure statement.

There is a $50 non-refundable processing fee for each abstract submission. Credit card payment must be made by selecting the Payment button. Payment must be made in order to complete the submission process. The abstract submission fee does not include meeting registration. If accepted, the presenting author of the abstract must register for the 2024 USCAP Annual Meeting.

Notification of receipt will be emailed to the primary contact following the payment. NOTE: It is the responsibility of the author to contact USCAP if confirmation of abstract receipt is not received within 1 business day. USCAP will confirm receipt of the abstract or assist authors to ensure that the abstract is complete.

Unless otherwise noted, all abstracts accepted for presentation at the USCAP Annual Meeting are embargoed from submission until the date and time of presentation. They cannot be presented in any national or international forum or be published (online or print) in abstract or manuscript form prior to the first day of the USCAP annual meeting. USCAP reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during the USCAP Annual Meeting.

If the accepted abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the Academy’s embargo policy. If publication occurs online or in print before the USCAP 2024 Annual Meeting, March 23-28, 2024, the abstract must be withdrawn. Please notify the Academy via e-mail at [email protected].